Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Time to Sell?

Posted by Stanley Muller on Jun 1st, 2026

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $9.44, but opened at $8.84. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.90, with a volume of 66,592 shares traded.

Analysts Set New Price Targets

Several brokerages have recently commented on SGIOY. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock has an average rating of “Hold”.

Check Out Our Latest Report on SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 5.1%

The company has a market cap of $15.08 billion, a price-to-earnings ratio of 11.08, a P/E/G ratio of 3.58 and a beta of 0.08. The firm has a 50-day moving average price of $10.14 and a 200 day moving average price of $9.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.03. The business had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%. Sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

(Get Free Report)

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.